Loading patent…
AssigneeNew York Blood Center, Inc.
InventorsBernard Horowitz, Jay E. Valinsky, Nicholas E. Geacintov, Bolanle Williams, Shanti B. Rywkin, Henrietta Nunno
Estimating the term…
The present invention concerns a process for inactivating an extracellular lipid enveloped human pathogenic virus and/or an intracellular human pathogenic virus which may be present in a blood cell composition containing ≧1×109 cells/ml by contacting that composition with a virucidally effective amount of at least one photoreactive compound having an absorption maximum of ≧630 nm, light and oxygen and/or a quencher. In one embodiment of the invention, the process is conducted under conditions whereby a structural integrity of greater than 80% of at least one type of blood cell contained within said composition is retained. Another embodiment of the invention relates to a process for inactivating an extracellular lipid enveloped human pathogenic virus and/or an intracellular human pathogenic virus which may be present in a composition containing at least one coagulation factor while retaining at least 77% of said coagulation factor by contacting said composition with a virucidally effective amount of at least one photoreactive compound, light and a quencher. The processes of the invention can be used to prepare blood products, which, in turn, are suitable for transfusion into a recipient in need of such transfusion.
A process for inactivating an extracellular lipid enveloped human pathogenic virus and/or an intracellular human pathogenic virus which may be present in a blood cell composition, comprising contacting said composition with a virucidally effective amount of a photoreactive compound having an absorption maximum of ≧630 nm, light and a quencher, wherein said composition contains ≧2.25×109 cells/ml.
A process for inactivating an extracellular lipid enveloped human pathogenic virus and/or a intracellular human pathogenic virus which may be present in a blood cell composition containing ≧2.25×109 cells/ml while retaining structural integrity of greater than 80% of one type of blood cell contained within said composition, comprising contacting said composition with a virucidally effective amount of at least one photoreactive compound having an absorption maximum of ≧630 nm, light and a quencher.
A process for inactivating a human immunodeficiency virus (HIV) which may be present in a blood cell composition containing ≧2.25×109 cells/ml while retaining structural integrity of greater than 80% of one type of blood cell contained within said composition, comprising contacting said composition with a virucidally effective amount of a photoreactive compound having an absorption maximum of ≧630 nm, light and a quencher.
A process for inactivating an extracellular lipid enveloped human pathogenic virus and/or an intracellular human pathogenic virus which may be present in a composition containing a coagulation factor while retaining ≧94% of said coagulation factor, consisting essentially of contacting said composition which a virucidally effective amount of a photoreactive compound, light and a quencher.
A process for inactivating a human immunodeficiency virus (HIV) which may be present in a composition containing at least one coagulation factor while retaining ≧94% of said coagulation factor, comprising contacting said composition with a virucidally effective amount of at least one photoreactive compound having an absorption maximum of ≧630 nm, light and a quencher.
Dependencies are inferred from the claim text.